Kymera Therapeutics Reveals Preclinical Data on Cancer-Fighting Drug KT-333 at AACR Meeting
Kymera Therapeutics Reveals Preclinical Data on Cancer-Fighting Drug KT-333 at AACR Meeting
Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that new preclinical data showing the structural and molecular mechanisms underlying anti-tumor activity of its novel STAT3 degrader, KT-333, were presented in a late-breaking research poster session at the AACR Annual Meeting taking place April 5-10, 2024, in San Diego, California. Additionally, Nello Mainolfi, PhD, Founder, President and CEO, will present in the Major Symposium at the conference highlighting the Company's unique target selection strategy and strong preclinical to clinical translation observed across the Company's first-in-class oncology programs, KT-333 and KT-253, a potent and selective degrader of MDM2.
Kymera Therapeutics, Inc.（納斯達克股票代碼：KYMR）是一家臨床階段的生物製藥公司，正在推進使用靶向蛋白質降解（TPD）的新型小分子藥物。該公司今天宣佈，在2024年4月5日至10日在聖地亞哥舉行的AACR年會的最新研究海報發佈會上公佈了顯示其新型 STAT3 降解劑 KT-333 抗腫瘤活性的結構和分子機制的新臨床前數據，加利福尼亞州。此外，創始人、總裁兼首席執行官Nello Mainolfi博士將在會議上的主要研討會上發表演講，重點介紹公司獨特的靶點選擇策略以及在公司首創的腫瘤項目 KT-333 和 KT-253（一種強效的選擇性MDM2降解劑）中觀察到的強大的臨床前到臨床轉化。
譯文內容由第三人軟體翻譯。